Sarepta Therapeutics' (SRPT) Sell Rating Reaffirmed at HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report)'s stock had its "sell" rating restated by investment analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $75.00 price target on the biotechnology company's stock. HC Wainwright's price objective points to a potential downside of 34.10% from the company's current price.

Several other analysts have also recently commented on the stock. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Wednesday, November 27th. Raymond James reiterated an "outperform" rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. Needham & Company LLC reiterated a "buy" rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Finally, Evercore ISI dropped their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $178.71.

Sarepta Therapeutics Stock Up 0.1 %

Shares of Sarepta Therapeutics stock traded up $0.09 during trading on Thursday, reaching $113.81. The company's stock had a trading volume of 604,263 shares, compared to its average volume of 838,451. The company has a 50-day simple moving average of $122.78 and a two-hundred day simple moving average of $126.72. Sarepta Therapeutics has a 1-year low of $102.15 and a 1-year high of $173.25. The company has a market cap of $10.87 billion, a price-to-earnings ratio of 91.05 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Insiders Place Their Bets

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the transaction, the director now owns 22,840 shares of the company's stock, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

Several large investors have recently made changes to their positions in SRPT. Manchester Capital Management LLC raised its position in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its position in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 156 shares during the period. Sunbelt Securities Inc. grew its position in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank increased its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new stake in Sarepta Therapeutics during the 4th quarter valued at $36,000. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.